Tracking Tweedy Browne Portfolio - Q4 2025 Update
Summarize this article with:
John Vincent26.01K FollowersFollow5ShareSavePlay(14min)CommentsSummaryTweedy Browne’s 13F portfolio rose to $1.24B in Q4 2025, with Ionis Pharma now the largest position at 15.74%.Significant stake increases were made in CNH Industrial, while major reductions occurred in Ionis and Alphabet.New position in UniFirst Corp. was initiated, while FMC Corporation was nearly exited after aggressive selling in previous quarters.The top five holdings—IONS, CNH, BRK.B, KOF, and GOOGL—comprise ~58% of the portfolio, reflecting concentrated conviction.
Getty Images This article is part of a series that provides an ongoing analysis of the changes made to Tweedy Browne’s 13F portfolio on a quarterly basis. It is based on Tweedy Browne’s regulatory 13F Form filed on 02/03/2026. PleaseThis article was written byJohn Vincent26.01K FollowersFollowFocused on analyzing 13F reports & building tools to help DIY investors generate absolute returns through exploiting inefficiency, volatility, and momentum.
Asymmetric Bets Focus. Broader commentary for DIY investors at Substack: https://diyabsolutereturns.substack.com/ . Check out my books in the Demystifying Web3 and Beyond series: 1. Demystifying Bitcoin: Paving the Way to Global Digital Money.2. Demystifying Crypto: Powering a Borderless Digital Economy.Analyst’s Disclosure: I/we have a beneficial long position in the shares of GOOGL, UHAL.B, DEO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.